INTRODUCTION: Depression therapy has been linked to negative effects on energy metabolism, which can be attributed to various factors, including an ongoing inflammatory process commonly seen in metabolic disorders. Unhealthy lifestyle choices of patients and the impact of antidepressants on body weight and lipid and glucose metabolism also contribute to these metabolic side effects. Although not as pronounced as other psychopharmaceuticals, the increasing use of antidepressants raises concerns about their potential impact on public health. The study aimed to evaluate the short- and long-term effects of the antidepressant citalopram and its long-term combination with a special diet on metabolic parameters in mice. METHODS: Animals were randomly divided into 5 groups - control, control + special diet, citalopram (10 mg/kg for 35 days), citalopram + special diet (10 mg/kg for 35 days), and citalopram (10 mg/kg for 7 days). After a described time of administration, animals were anesthetized, blood and fat and liver tissues were collected. Biochemical parameters of lipid metabolism (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) and glucose were analyzed using spectrophotometry and relevant adipokines and cytokines were evaluated by ELISA. RESULTS: After a week of application of citalopram, we observed dyslipidemia that persisted even at the end of the 5-week experiment. Furthermore, after 5 weeks of citalopram administration, we observed a significant decrease in body weight gain and decreased leptin levels. Changes in lipid metabolism, higher levels of adipokines leptin and PAI-1 were observed due to the special diet after 5 weeks. CONCLUSIONS: Our research suggests that the effects of citalopram and a diet on the metabolism of mice can be significant, both in the short term (1 week) and in the long term (5 weeks).

• Klíčová slova
• Adipokines, Citalopram, Dyslipidemia, Leptin, Metabolic syndrome, Mouse,
• MeSH
• citalopram * škodlivé účinky   aplikace a dávkování   farmakologie   MeSH
• dieta s vysokým obsahem tuků škodlivé účinky   MeSH
• dyslipidemie * chemicky indukované   krev   metabolismus   MeSH
• glukosa * metabolismus   MeSH
• játra metabolismus   účinky léků   MeSH
• krevní glukóza metabolismus   účinky léků   MeSH
• leptin * krev   metabolismus   MeSH
• lipidy * krev   MeSH
• metabolismus lipidů * účinky léků   MeSH
• myši MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• citalopram * MeSH
• glukosa * MeSH
• krevní glukóza MeSH
• leptin * MeSH
• lipidy * MeSH

Lipidated anorexigenic peptides are highly promising compounds for the treatment of obesity and related diseases. However, their exact mechanism of action still remains unknown. We labelled a lipidated analogue of an anorexigenic prolactin-releasing peptide (palm11-PrRP31) with an extremely stable ClickZip lanthanide tag, facilitating tracking of the peptide within the organism. We then employed a separation method based on liquid chromatography combined with inductively coupled plasma mass spectrometry (LC-ICP-MS). This technique involved the use of an unconventional mobile phase containing 5 % 1,2-hexanediol in H2O (v/v) with the addition of 2 % formic acid. Using a rapid. 6-min analysis, we were able to quantify the ClickZip tag - and thus indirectly the fate of the labelled peptides in the living organism - independently of free Ln3+ ions. The detection limits for the various lanthanide chemical forms were extremely low, ranging between 0.9 and 3.4 ng/L. We demonstrated the suitability of the method for analysing real biological samples like blood plasma, and confirmed the accuracy of our results. Prior to LC-ICP-MS analysis, we optimised a process involving the microwave-assisted digestion of liver samples to preserve the integrity of the ClickZip tag. We also identified several metabolites of the labelled peptides in the liver, urine, and blood plasma, highlighting the utility of the method for revealing the mechanism of action behind the labelled lipopeptides.

• Klíčová slova
• 1,2-Hexanediol, Anorexigenic peptides, Method validation, Sample digestion,
• MeSH
• chromatografie kapalinová metody   MeSH
• click chemie MeSH
• hmotnostní spektrometrie * metody   MeSH
• hormon uvolňující prolaktin chemie   MeSH
• játra chemie   metabolismus   MeSH
• lanthanoidy chemie   MeSH
• myši MeSH
• peptidy chemie   analýza   MeSH
• zvířata MeSH
• Check Tag
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• hormon uvolňující prolaktin MeSH
• lanthanoidy MeSH
• peptidy MeSH

Accumulation of extracellular matrix (ECM) in liver fibrosis is associated with changes in protein abundance and composition depending upon etiology of the underlying liver disease. Current efforts to unravel etiology-specific mechanisms and pharmacological targets rely on several models of experimental fibrosis. Here, we characterize and compare dynamics of hepatic proteome remodeling during fibrosis development and spontaneous healing in experimental mouse models of hepatotoxic (carbon tetrachloride [CCl4] intoxication) and cholestatic (3,5-diethoxycarbonyl-1,4-dihydrocollidine [DDC] feeding) injury. Using detergent-based tissue extraction and mass spectrometry, we identified compartment-specific changes in the liver proteome with detailed attention to ECM composition and changes in protein solubility. Our analysis revealed distinct time-resolved CCl4 and DDC signatures, with identified signaling pathways suggesting limited healing and a potential for carcinogenesis associated with cholestasis. Correlation of protein abundance profiles with fibrous deposits revealed extracellular chaperone clusterin with implicated role in fibrosis resolution. Dynamics of clusterin expression was validated in the context of human liver fibrosis. Atomic force microscopy of fibrotic livers complemented proteomics with profiles of disease-associated changes in local liver tissue mechanics. This study determined compartment-specific proteomic landscapes of liver fibrosis and delineated etiology-specific ECM components, providing thus a foundation for future antifibrotic therapies.

Alcoholism or chronic conditions like hepatitis damage the liver. Over time, scar tissue builds up in the liver, causing cirrhosis. The scaring results from the liver’s repeated attempts to repair itself by creating more structural proteins called extracellular matrix proteins. A buildup of these scaffolding proteins leads to tissue stiffening or fibrosis. Fibrosis may heal in some cases but in others, it may progress to cirrhosis, liver cancer or liver failure. Learning more about these processes may help scientists and clinicians understand why fibrosis is reversible in some cases but not others. It may also allow them to develop treatments that can treat or reverse fibrosis and prevent cirrhosis, liver cancer, or liver failure. The first step is studying how fibrosis occurs in mouse models that mimic different types of liver disease. For example, repetitive ingestion of a toxic substance, such as alcohol, can cause one type of liver disease. However, slowing or stalling bile flow through the biliary system (the liver, gallbladder, and bile ducts), leads to a different type of chronic liver injury. Jirouskova et al. identify an extracellular protein called clusterin that may help heal fibrosis. The experiments used mouse models of two different types of liver disease. One mimicked liver disease caused by repetitive toxin injury, and the other modelled liver disease caused by chronic stalling of the bile flow in the liver (cholestasis). In the experiments, Jirouskova et al. looked at all the proteins made in each type of liver disease as the animals developed fibrosis or their fibrosis resolved. They also studied extracellular matrix proteins and how they affected molecular signaling in the liver tissue. The experiments revealed different patterns of protein production and healing in the different types of liver disease. The animals with liver diseases caused by chronic cholestatic injury were less likely to heal their livers and showed potential to progress to liver cancer. Production of the clusterin protein was connected with better liver recovery from toxic injuries. Jirouskova et al. provide a comprehensive map of all the proteins produced over the course of liver fibrosis progression and healing in two different animal models of liver disease. Scientists and clinicians may use this information to study liver disease types. It may also one day help them personalize patient's therapies. The experiments show that extracellular matrix proteins are essential contributors to fibrosis and key signaling agents in liver disease. This may make them good targets for new therapies. Boosting clusterin production may be one approach to promoting liver recovery. More studies are needed to confirm this before such therapies can be developed and tested in humans.

• Klíčová slova
• atomic force microscopy, clusterin, collagen deposits, human, mass spectrometry, matrisome, medicine, mouse,
• MeSH
• chlorid uhličitý toxicita   MeSH
• cholestáza * metabolismus   chemicky indukované   patologie   MeSH
• extracelulární matrix metabolismus   MeSH
• jaterní cirhóza * metabolismus   patologie   chemicky indukované   MeSH
• játra * patologie   metabolismus   MeSH
• lidé MeSH
• modely nemocí na zvířatech MeSH
• myši inbrední C57BL MeSH
• myši MeSH
• proteom * metabolismus   analýza   MeSH
• proteomika MeSH
• pyridiny MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• 3,5-diethoxycarbonyl-1,4-dihydrocollidine MeSH Prohlížeč
• chlorid uhličitý MeSH
• proteom * MeSH
• pyridiny MeSH

High-salt diets (HSDs) are known to impact blood pressure and cardiovascular health, but their effects on glucose metabolism, liver function, and gut microbiota remain poorly understood. This study investigates how long-term HSD affects these physiological processes and evaluates the potential therapeutic effects of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). Male Sprague-Dawley rats were fed a normal salt diet (0.3% NaCl), a moderate salt diet (2% NaCl), or a high-salt diet (8% NaCl) for 12 wk. Two subgroups in the HSD condition received telmisartan or enalapril. We assessed blood pressure, glucose homeostasis, liver inflammation, pancreatic function, and gut microbiota composition. HSD rats exhibited significantly higher blood pressure [130 ± 2 mmHg in normal diet (ND) vs. 144 ± 4 mmHg in HSD; P < 0.01], reduced fasting insulin (1.33 ± 0.14 ng/mL in ND vs. 0.60 ± 0.05 ng/mL in HSD; P < 0.01), and gut microbiota dysbiosis, with a 71% reduction in Ruminococcus species (P = 0.018). Liver inflammation, indicated by an increase in CD68+ macrophages, was also observed in the HSD group. Telmisartan treatment significantly reduced liver inflammation but did not fully restore metabolic homeostasis. HSD disrupts multiple physiological systems, including glucose metabolism and liver function, partly through gut microbiota alterations. ACEIs and ARBs provided partial protection, highlighting the need for multitargeted interventions to mitigate high-salt diet effects.NEW & NOTEWORTHY High-salt diet induces multisystem disruptions, including liver inflammation, reduced insulin levels, and gut microbiota imbalance. ACEIs and ARBs showed limited efficacy, highlighting the need for comprehensive therapeutic approaches.

• Klíčová slova
• ACE inhibitor, angiotensin II receptor blocker, high-salt diet, rat physiology,
• MeSH
• antagonisté receptorů pro angiotenzin * farmakologie   MeSH
• enalapril farmakologie   MeSH
• glukosa * metabolismus   MeSH
• inhibitory ACE * farmakologie   MeSH
• játra * účinky léků   metabolismus   MeSH
• krevní glukóza metabolismus   účinky léků   MeSH
• krevní tlak účinky léků   MeSH
• krysa rodu Rattus MeSH
• kuchyňská sůl * škodlivé účinky   MeSH
• potkani Sprague-Dawley MeSH
• střevní mikroflóra * účinky léků   MeSH
• telmisartan farmakologie   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• antagonisté receptorů pro angiotenzin * MeSH
• enalapril MeSH
• glukosa * MeSH
• inhibitory ACE * MeSH
• krevní glukóza MeSH
• kuchyňská sůl * MeSH
• telmisartan MeSH

LIM and Src homology 3 (SH3) protein 2 (LASP2) is a small focal adhesion protein first identified as a splice variant of the nebulette gene (Nebl). As the newest member of the nebulin protein family, the regulation and function of LASP2 remain largely unknown. Our previous RNA-sequencing results identified Nebl as one of the most highly induced genes in the mouse liver in response to the activation of pregnane X receptor (PXR). In this study, we investigated this phenomenon further and show that PXR induces Lasp2 instead of Nebl, which partially use the same exons. Lasp2 was found to be induced in response to PXR ligand pregnenolone 16α-carbonitrile (PCN) treatment in mouse liver in vivo both after 4-day treatment and after long-term, 28-day treatment and in both male and female mice. Interestingly, the Lasp2 induction was more efficient in high-fat diet-fed mice (103-fold after 4-day PCN treatment) than in the normal chow-fed mice (32-fold after 4-day PCN treatment). Lasp2 induction was abolished in PXR knockout mice but could be rescued by re-expression of PXR, indicating that Lasp2 induction is PXR mediated. In mouse primary hepatocytes cycloheximide did not inhibit Lasp2 induction by PCN and a PXR binding site could be recognized upstream of the mouse Lasp2 gene suggesting direct regulation of Lasp2 by PXR. In human 3D hepatocytes, rifampicin induced only a modest increase in LASP2 expression. This study shows for the first time that PXR activation strongly induces Lasp2 expression in mouse liver and establishes Lasp2 as a novel PXR target gene. SIGNIFICANCE STATEMENT: RNA-sequencing results have previously identified nebulette (Nebl) to be efficiently induced by pregnane X receptor activating compounds. This study shows that instead of Nebl, LIM and Src homology 3 (SH3) protein 2 (Lasp2) coding for a small focal adhesion protein and partly sharing exons with the Nebl gene is a novel target of pregnane X receptor in mouse liver.

• Klíčová slova
• LASP2, Liver, Nebulette, Pregnane X receptor, Pregnenolone-16α-carbonitrile, Rifampicin,
• MeSH
• adaptorové proteiny signální transdukční genetika   metabolismus   MeSH
• cytoskeletální proteiny * genetika   metabolismus   MeSH
• hepatocyty metabolismus   účinky léků   MeSH
• játra * metabolismus   účinky léků   MeSH
• lidé MeSH
• myši inbrední C57BL * MeSH
• myši knockoutované * MeSH
• myši MeSH
• pregnanový X receptor * genetika   metabolismus   MeSH
• pregnenolonkarbonitril farmakologie   MeSH
• proteiny s doménou LIM * genetika   metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• myši MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• adaptorové proteiny signální transdukční MeSH
• cytoskeletální proteiny * MeSH
• pregnanový X receptor * MeSH
• pregnenolonkarbonitril MeSH
• proteiny s doménou LIM * MeSH

Liver sinusoidal endothelial inflammation/dysfunction and fibrosis are a crucial part of Metabolic Dysfunction Associated Steatohepatitis (MASH) development. TRC105 and M1043 are anti-endoglin (ENG) monoclonal antibodies that bind ENG. In this study, we hypothesized that treatment with anti-ENG antibodies would prevent the progression of LSECs inflammation and fibrosis in vivo and in vitro. MASH was induced in male C57BL/6 mice fed a choline-deficient L-amino acid-defined high-fat diet (CDAA-HFD) for 4 or 8 weeks. In the rescue study, mice were divided into three groups: a control group (chow diet), a MASH group (CDAA-HFD + IgG), and a rescue group (CDAA-HFD + M1043). Later, two groups received rat IgG1 (10 mg/kg) and M1043 (10 mg/kg). In in vitro experiments, inflammation was induced in human LSECs by ox-LDL (50 μg/mL) and treated with TRC105 (300 μg/mL). Liver sinusoidal endothelial inflammation/dysfunction in MASH animals was characterized by endothelial overexpression of ENG, VCAM-1, and ICAM-1 and reduced VE-cadherin and p-eNOS/eNOS expression. M1043 treatment prevented the overexpression of ENG, VCAM-1, and ICAM-1, the progression of liver fibrosis, and the increase of liver-to-body weight ratio. In vitro experiments with TRC105 confirmed the prevention of LSECs inflammation development by reduced ENG and VCAM-1 expression, as well as decreased THP-1 monocytic cell adhesion in ox-LDL activated LSECs. In conclusion, we demonstrate that anti-ENG antibody treatment can prevent LSECs inflammation and fibrosis progression in a MASH animal model and LSECs inflammation in vitro. Thus, we propose directly targeted ENG may represent a promising pharmacological approach for addressing LSECs inflammation and liver fibrosis.

• Klíčová slova
• Anti-endoglin antibody, Endoglin, Fibrosis, Liver alteration, Liver sinusoidal endothelial inflammation,
• MeSH
• dieta s vysokým obsahem tuků škodlivé účinky   MeSH
• endoglin * metabolismus   antagonisté a inhibitory   MeSH
• endoteliální buňky účinky léků   metabolismus   patologie   MeSH
• jaterní cirhóza * prevence a kontrola   patologie   farmakoterapie   metabolismus   MeSH
• játra * patologie   účinky léků   metabolismus   MeSH
• krysa rodu Rattus MeSH
• lidé MeSH
• monoklonální protilátky * farmakologie   MeSH
• myši inbrední C57BL * MeSH
• myši MeSH
• nealkoholová steatóza jater farmakoterapie   prevence a kontrola   patologie   metabolismus   MeSH
• progrese nemoci MeSH
• zánět * patologie   farmakoterapie   metabolismus   prevence a kontrola   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• lidé MeSH
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• endoglin * MeSH
• monoklonální protilátky * MeSH

Propiconazole is a triazole fungicide previously shown to induce triglyceride accumulation in human liver HepaRG cells, potentially via activation of the Pregnane X Receptor (PXR). However, whether propiconazole can disrupt hepatic and whole-body metabolism in vivo is currently unknown. Therefore, we aimed to examine the metabolic effects of propiconazole in the context of metabolic dysfunction-associated steatotic liver disease (MASLD), obesity, and insulin resistance. To this end, male C57BL/6J mice were fed a high-fat diet for 20 weeks. During the last 10 weeks, mice additionally received vehicle, 0.04, 30, or 100 mg/kg body weight (bw)/day propiconazole via oral gavage. High-dose propiconazole, but not low or intermediate dose, reduced body weight gain and adipose tissue weight in obese mice. Mice receiving high-dose propiconazole displayed improved glucose tolerance and reduced levels of plasma triglycerides and cholesterol. Propiconazole dose-dependently increased liver weight and triglyceride levels and at high dose caused signs of hepatic inflammation. RNA sequencing on the liver revealed that propiconazole mainly induced PXR target genes. At intermediate and high dose, propiconazole induced pathways related to cell-cell interactions and inflammation, while oxidative phosphorylation was repressed by propiconazole. Comparison of gene regulation in wildtype and PXR knockout primary hepatocytes as well as gene reporter assays confirmed the activation of PXR by propiconazole. All in all, our data underscore the capacity of propiconazole to activate PXR in the liver and thereby promote the development of hepatic steatosis in vivo.

• Klíčová slova
• Lipid metabolism, Liver, MASLD, Metabolism disrupting chemicals (MDCs), Nuclear receptors/PXR, Propiconazole,
• MeSH
• dieta s vysokým obsahem tuků * MeSH
• inzulinová rezistence MeSH
• játra účinky léků   metabolismus   patologie   MeSH
• modely nemocí na zvířatech MeSH
• myši inbrední C57BL * MeSH
• myši MeSH
• obezita * chemicky indukované   MeSH
• pregnanový X receptor * metabolismus   genetika   MeSH
• průmyslové fungicidy * toxicita   MeSH
• triazoly * toxicita   MeSH
• triglyceridy krev   metabolismus   MeSH
• vztah mezi dávkou a účinkem léčiva MeSH
• ztučnělá játra * chemicky indukované   MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• pregnanový X receptor * MeSH
• propiconazole MeSH Prohlížeč
• průmyslové fungicidy * MeSH
• triazoly * MeSH
• triglyceridy MeSH

Chronic Kidney Disease (CKD) is associated with heightened risk of thrombosis. Prescription of anticoagulants is key to manage it; however, CKD patients have shown an increased risk of bleeding under anticoagulation therapy compared to non-CKD patients. We hypothesized that the sex could modify the metabolism of indoxyl sulfate (IS), a uremic toxin and Apixaban. Our intoxication model shows that higher doses of IS and apixaban accumulate in the plasma of female mice because of expression differences in efflux transporters and cytochromes in the liver, ileum and kidneys, when compared to males. Furthermore, we found that accumulation of apixaban in females contributes to increased bleeding. Transcriptional analysis of liver samples revealed elevated Sult1a1 but reduced Abcg2 and Cyp3a11 in female mice, while in the kidneys the expression rates of Oat1 and Oat3 were respectively lower and higher than those observed in males, potentially affecting drug clearance. Whole proteomics liver analysis confirmed the previous transcriptional results at the protein level and revealed that sex had a major influence in regulating both coagulation and drug metabolism pathways. Thus, our findings underline the need for inclusive clinical and preclinical trials to accurately reflect sex-specific metabolic variations, and to consider CKD-specific changes to optimize dosing, minimize side effects, and improve patient outcomes.

• MeSH
• ABC transportér z rodiny G, člen 2 metabolismus   genetika   MeSH
• antikoagulancia aplikace a dávkování   metabolismus   MeSH
• chronická renální insuficience metabolismus   farmakoterapie   MeSH
• cytochrom P-450 CYP3A metabolismus   genetika   MeSH
• indican * metabolismus   krev   MeSH
• játra * metabolismus   účinky léků   MeSH
• krvácení metabolismus   MeSH
• ledviny metabolismus   účinky léků   MeSH
• myši inbrední C57BL MeSH
• myši MeSH
• přenašeče organických aniontů nezávislé na sodíku metabolismus   genetika   MeSH
• protein 1 přenášející organické anionty metabolismus   genetika   MeSH
• pyrazoly * farmakologie   MeSH
• pyridony * aplikace a dávkování   metabolismus   farmakologie   MeSH
• sexuální faktory MeSH
• zvířata MeSH
• Check Tag
• mužské pohlaví MeSH
• myši MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• ABC transportér z rodiny G, člen 2 MeSH
• antikoagulancia MeSH
• apixaban MeSH Prohlížeč
• cytochrom P-450 CYP3A MeSH
• indican * MeSH
• organic anion transport protein 3 MeSH Prohlížeč
• přenašeče organických aniontů nezávislé na sodíku MeSH
• protein 1 přenášející organické anionty MeSH
• pyrazoly * MeSH
• pyridony * MeSH

Constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are closely related nuclear receptors with overlapping regulatory functions in xenobiotic clearance but distinct roles in endobiotic metabolism. Car activation has been demonstrated to ameliorate hypercholesterolemia by regulating cholesterol metabolism and bile acid elimination, whereas PXR activation is associated with hypercholesterolemia and liver steatosis. Here we show a human CAR agonist/PXR antagonist, MI-883, which effectively regulates genes related to xenobiotic metabolism and cholesterol/bile acid homeostasis by leveraging CAR and PXR interactions in gene regulation. Through comprehensive analyses utilizing lipidomics, bile acid metabolomics, and transcriptomics in humanized PXR-CAR-CYP3A4/3A7 mice fed high-fat and high-cholesterol diets, we demonstrate that MI-883 significantly reduces plasma cholesterol levels and enhances fecal bile acid excretion. This work paves the way for the development of ligands targeting multiple xenobiotic nuclear receptors. Such ligands hold the potential for precise modulation of liver metabolism, offering new therapeutic strategies for metabolic disorders.

• MeSH
• cholesterol * metabolismus   krev   MeSH
• cytochrom P-450 CYP3A metabolismus   genetika   MeSH
• dieta s vysokým obsahem tuků * škodlivé účinky   MeSH
• hypercholesterolemie * farmakoterapie   metabolismus   MeSH
• hypolipidemika farmakologie   terapeutické užití   MeSH
• játra metabolismus   účinky léků   MeSH
• konstitutivní androstanový receptor * MeSH
• lidé MeSH
• metabolismus lipidů účinky léků   MeSH
• modely nemocí na zvířatech MeSH
• myši inbrední C57BL MeSH
• myši MeSH
• pregnanový X receptor * metabolismus   genetika   MeSH
• pyridiny MeSH
• receptory cytoplazmatické a nukleární * metabolismus   agonisté   genetika   MeSH
• regulace genové exprese účinky léků   MeSH
• žlučové kyseliny a soli * metabolismus   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• myši MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• 1,4-bis(2-(3,5-dichloropyridyloxy))benzene MeSH Prohlížeč
• cholesterol * MeSH
• cytochrom P-450 CYP3A MeSH
• hypolipidemika MeSH
• konstitutivní androstanový receptor * MeSH
• pregnanový X receptor * MeSH
• pyridiny MeSH
• receptory cytoplazmatické a nukleární * MeSH
• žlučové kyseliny a soli * MeSH

AIM: Exposure to light at night and meal time misaligned with the light/dark (LD) cycle-typical features of daily life in modern 24/7 society-are associated with negative effects on health. To understand the mechanism, we developed a novel protocol of complex chronodisruption (CD) in which we exposed female rats to four weekly cycles consisting of 5-day intervals of constant light and 2-day intervals of food access restricted to the light phase of the 12:12 LD cycle. METHODS: We examined the effects of CD on behavior, estrous cycle, sleep patterns, glucose homeostasis and profiles of clock- and metabolism-related gene expression (using RT qPCR) and liver metabolome and lipidome (using untargeted metabolomic and lipidomic profiling). RESULTS: CD attenuated the rhythmic output of the central clock in the suprachiasmatic nucleus via Prok2 signaling, thereby disrupting locomotor activity, the estrous cycle, sleep patterns, and mutual phase relationship between the central and peripheral clocks. In the periphery, CD abolished Per1,2 expression rhythms in peripheral tissues (liver, pancreas, colon) and worsened glucose homeostasis. In the liver, it impaired the expression of NAD+, lipid, and cholesterol metabolism genes and abolished most of the high-amplitude rhythms of lipids and polar metabolites. Interestingly, CD abolished the circadian rhythm of Cpt1a expression and increased the levels of long-chain acylcarnitines (ACar 18:2, ACar 16:0), indicating enhanced fatty acid oxidation in mitochondria. CONCLUSION: Our data show the widespread effects of CD on metabolism and point to ACars as biomarkers for CD due to misaligned sleep and feeding patterns.

• Klíčová slova
• acylcarnitine, chronodisruption, clock, female, glucose homeostasis, liver, metabolome, pancreas, rat, sleep, suprachiasmatic nucleus,
• MeSH
• cirkadiánní hodiny fyziologie   MeSH
• cirkadiánní rytmus * fyziologie   MeSH
• fotoperioda MeSH
• játra * metabolismus   MeSH
• karnitin * analogy a deriváty   metabolismus   MeSH
• krysa rodu Rattus MeSH
• metabolom * MeSH
• nucleus suprachiasmaticus metabolismus   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• acylcarnitine MeSH Prohlížeč
• karnitin * MeSH